Seqirus, a global leader in influenza prevention, announced that its cell-based quadrivalent influenza vaccine (QIVc) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for use in people aged 9 years and above. Subject to final approval by the European Commission, Seqirus plans to launch the vaccine as FLUCELVAX TETRA in Europe for the 2019/20 influenza season.
Ook interessant voor je
![[onderzoek] Marketeers balanceren tussen AI en authentieke merkbeleving](https://www.pharmamarketeer.nl/wp-content/uploads/2025/03/167284-80x60.jpg)
Reageer